Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

Inclusion Criteria: * Patient 18 years and older * Confirmed pulmonary TB (positive Mtb culture or positive polymerase chain reaction (PCR) Mtb-complex) * Intended to start on first-line TB treatment * HIV negative * BMI \>17 * Written Informed Consent * Women of childbearing potential should agree on adequate contraceptives during treatment period and have a negative pregnancy test prior to treatment initiation Exclusion Criteria: * Not able to provide informed consent/unable to assimilate study information * Concomitant infectious disease that requires treatment * Known allergy to rifamycins, isoniazid, pyrazinamide, ethambutol or history of severe sideeffect to any of the drugs * Drug-induced inflammatory liver diseases in medical history * History of acute liver disease * On-going liver disease including hepatitis and elevated transaminase levels \>x5 upper normal limit * Porphyria * Drug-drug interaction between concomitant drugs and rifampicin that could not be bridged by dose-adjustment of the concomitant drug * Jaundice * Acute gout * Treatment of active TB during the last year * Drug resistance to RIF, INH, PZA or EMB * Miliary TB * Pulmonary TB with smear positivity grade 3 and/or chest X-ray grading equal to advanced TB * TB in the central nervous system * Extrapulmonary TB (outside central nervous system) without pulmonary TB * Pregnancy and breast-feeding * Immunosuppressive condition * Heart failure (NYHA class III and IV) * Renal failure with estimated glome…